Most Popular Products
CRISPR Gene Editing
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein Purification
Proteins
Molecular Biology
Stable Cell Lines
Cell Therapy
Diagnostics
Resources
GenScript's proprietary TurboCHO™ platform offers high throughput production of purified antibodies, featuring the market's fastest turnaround time—just 5 business days from gene to antibody. With a large capacity of 30,000+ targets/month, TurboCHO™ ensures a seamless production. With premium quality, this platform provides a cost-effective and time-efficient solution for various stages of antibody research, including lead characterization, antibody engineering, humanization, affinity maturation, and more.
Additionally, we provide scalable options to meet your antibody needs, ranging from early screening stages to in vivo studies.
5 business days from gene to antibody
High yields achieving gram-level outputs
Competitive price
from $120/Ab
70+ different formats of bsAbs
Gene to Hits
10µg-10mg
Hits to Leads
10mg-1g
Candidates Selection
1g-200g
Patient Response
Manufacture
Scale
TurboCHO™ High
Throughput >>
Designed for high-throughput screening, as fast as 5 Business Days
TurboCHO™
Express >>
Yield up to gram, starting at 2 weeks
TurboCHO™ High Performance >>
Yield up to gram, from 6-7 weeks
TurboCHO™ Stable Cell Pool &
Cell
Line >>
High Expression Level and High-Quality Products with
ECACC-Licensed CHO-K1 Cell
70+ Bi-specific Antibody Formats Produced
TurboCHO™ Bi-specific Antibody Expression
>>
Yield up to gram, high binding affinity
and purity
Ron Deckelbaum
Regeneron Pharmaceuticals Inc.
We tasked the GenScript team with challenging projects for the production of engineered proteins that were novel and not necessarily straightforward. The GenScript team demonstrated a high level of commitment both timelines and quality product delivery.
Excellent quality and fast services, with a vast offer of molecular biology and protein/antibody products. The technical support is particularly helpful in finding the best solution for the specific experimental needs.
Dr. Gabriele Casirati
Boston Children's Hospital
David G.Harrison
Vanderbilt University
GenScript has been very helpful for years. I consider them part of my lab. Rather than spending weeks and months expressing proteins, I get turn around on orders in a few weeks, and am never disappointed.
Over the past few years, GenScript has become an indispensable partner in our research endeavors. Moreover, their custom protein services have been a game-changer. The purity and functionality of the proteins we’ve ordered have always met, if not exceeded, our expectations.
Victoria McGilligan
Ulster University
hIgG mAb Production
Conclusion: 81.4% of TurboCHO™ hIgG mAb projects have achieved a yield of ＞200 mg/L, and 7.1% can achieved a yield of ＞800 mg/L. 68% of the projects have attained a purity level ＞95%.
mIgG mAb Production
Conclusion: 75.5% of TurboCHO™ mIgG mAb projects have achieved a yield of ＞200 mg/L, and 7.7% can achieved a yield of ＞800 mg/L. 74% of the projects have attained a purity level ＞95%.
Conclusion: With TurboCHO™ 2.0 High Throughput platform, high-titer expression (＞200 mg/L) was demonstrated for a variety of antibodies, such as hIgG1/4, mIgG2a/2b, rabbit, and bsAb.
| Target | Host cell Line | Expression Volume (ml) | Concentration (mg/ml) | Purity SDS-PAGE (%) | Purity SEC-HPLC (%) | Endotoxin Level (EU/mg) | Total (mg) |
|---|---|---|---|---|---|---|---|
| Full length IgG1 (Batch 1) | CHO-Express | 1000 | 9.06 | 90 | 98 | ≤0.1 | 480.18 |
| Full length IgG1 (Batch 2) | CHO-Express | 1000 | 11.93 | 90 | 98 | ≤0.1 | 489.13 |
| Full length IgG1 (Batch 3) | CHO-Express | 1000 | 14.15 | 90 | 98 | ≤0.1 | 516.47 |
Conclusion: Three batches of full length IgG1 has been produced with high purity (＞98%) and high yields (＞480 mg/L), demonstrating consistent performance.
Conclusion: 82.1% of hIgG1 have achieved a yield of ＞200 mg/L, and 12.2% can achieved a yield of ＞400 mg/L. 97.8% of the samples have attained a purity level ＞95%. 1090 hIgG1 have been produced in 14 days.
Figure 1. Concentration Distribution of VHH (mg/ml)
95% of the VHH has reached a concentration level ≥ 50%.
Figure 2. Purity of VHH by HPLC (%)
89.8% VHH have attained a purity level ≥ 80%.
Figure 3. Yield of VHH (mg/L)
94% VHH have achieved a yield of ＞125 mg/L.
VHH have been produced in 15 days.
Conclusion:
Challenge: BsAb1 different chains exhibit varying expression levels, leading to low yield and purity when transfected with an equal molar plasmid ratio.
Solution: Optimize the plasmid ratio during transfection.
Result: A chain ratio of 2:2:5 provides optimal purity and yield.
Challenge: One-step purification results in a high percentage of aggregation.
Solution: Select the optimal affinity column for one-step purification.
Result: Pro-G purification demonstrated higher purity and yield compared to CH1 purification for this Fab-ScFv BsAb.
Challenge: Yields of various bsAbs are relatively low with TurboCHO™ 1.0.
Solution: Optimize the cell line and vector in the upgraded TurboCHO™ 2.0.
Result: The yields of these bsAbs with TurboCHO™ 2.0 have significant increases compared to those achieved with TurboCHO™ 1.0.
How to Optimize Transient Gene Expression in CHO Cells for Recombinant Antibody
May 23, 2024, Editor: Sean Huang
Learn More
Bispecific Antibodies: Platforms and Challenges Revealed
Exploring the Versatility of Bispecific Antibodies in Targeted Therapeutics
Apr 22, 2024, Rosa Moreno
Learn More
AI-based Antibody Therapeutics Developability Assessment and Its Engineering
Although mAbs represent the fastest-growing sector in therapeutics, their development is complex, with developability being a crucial consideration. Developability evaluates the potential of an antibody candidate to be produced as a safe and effective drug.
June 21, 2024, Carter Hao
Learn More
Bispecific Antibody Overview & Production with CrossMab Technology
The webinar will introduce the advantages of bispecific antibodies (bsAbs), their mechanism of action (MOA), and the development history of bsAb platform.
June 18, 2024, Wang Sai
Learn MoreEmpowered by GenScript’s TurboCHO™ expression system, our high throughput gene to antibody service enables the fastest “Gene to Target” delivery. From sequence to purified antibody, in as short as 5 business days, TurboCHO™ HT cost-effectively expedites the screening of therapeutic targets. Moving along the discovery workflow, the TurboCHO™ Express service provides a better solution for therapeutic lead expression and optimization and diagnostic biomarker discovery. Finally, once the lead is identified, our TurboCHO™ HP stable expression service is designed to support the flow of drugs into clinical evaluation or diagnostic assay development. By implementing an effective mitigation strategy through gram levels of antibody production while keeping a high-quality standard based on comprehensive QC specs, both TurobCHO™ HP and TurobCHO™ Stable provide a leading-edge on candidate selection.
Antibody/Protein Therapeutics
Diagnostic
"CHO cells" or Chinese Hamster Ovary cells have a long history as tools for the generation of biological therapeutics (i.e. monoclonal antibodies, enzymes, cytokines, and hormones). CHO cell-derived monoclonal antibodies have been approved to treat a broad range of indications, including cancer, multiple sclerosis, asthma, HIV, and neuroblastoma. Several favorable properties have driven CHO cells' increased use in bioprocessing, including their resilience to growth conditions, resistance to viral infections, and high protein synthesis capacity. Significantly, protein-processing by CHO cells more closely conserves the post-translational modifications (e.g., glycosylation) and folding found in human proteins.
On top of that, consistent use of a specific cell expression system across the early and late biotherapeutic protein development stages is critical. For example, the use of CHO transit expression in therapeutic monoclonal antibody development expedites the availability of smaller quantities of antibody candidates, ideal for preliminary in vitro testing. Higher-yield stable CHO expression of lead recombinant monoclonal antibodies is a recommended path towards later preclinical stages. This approach increases the probability that candidates for pharmacological and toxicological characterization conserve established glycosylation patterns supporting IND and therapeutic development.
